A trial fibrillation (AF) is the most common arrhythmia in clinical practice and increases the risk of ischemic stroke in the general population. 1, 2 The development of AF is strongly associated with age, 3 and the prevalence of AF is >15% in individuals >75 years old. [4] [5] [6] [7] Patients with congenital heart disease (CHD) are assumed to be vulnerable to AF and atrial flutter because of previous or persistent volume or pressure overload, comorbidities, and postintervention scarring. Previous data indicate that atrial arrhythmias occur in 15.1% of adult patients with CHD and are associated with an increased risk of cardiovascular morbidities and mortality compared with adult patients with CHD but without atrial arrhythmias. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Given the dramatic evolution of reconstructive congenital heart surgery over time 19 and the increased risk of maternal and obstetric complications during pregnancy, 20 the risk of AF by time period and by sex is of major interest.
The present study was performed to evaluate the risk of developing AF in children and young adults with CHD compared with control subjects and to determine major complications associated with AF in this group of patients.
METHODS

Study Population
We used data from the Swedish National Patient Register to identify patients with a CHD diagnosis at any time. All diagnoses were coded according to the International Statistical Classification of Diseases, Eighth Revision (ICD-8), Ninth Revision (ICD-9), and Tenth Revision (ICD-10).
We identified 21 982 patients with any CHD diagnosis who were born from January 1970 to December 1993 and who were registered in the National Hospital Inpatient, Outpatient, or National Cause of Death registers in Sweden. Follow-up and comorbidity data were collected until the end of the study (December 31, 2011), a diagnosis of AF, or death. Each patient with CHD was matched by birth year, sex, and county with 10 control subjects without a diagnosis of CHD from the Total Population Register in Sweden. The study population has been described previously. 19, 21 The study was approved by the Gothenburg Regional Research Ethics Board and complied with the Declaration of Helsinki. The Swedish National Board of Health and Welfare replaced all national registration numbers with a unique code for every individual in our final data set; informed consent was therefore waived.
The data, analytical methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Definitions
CHD was defined as present in any patient with at least 1 outpatient visit, a hospital discharge, or a death certificate with at least 1 registered ICD code diagnosis of CHD from 1970 to 2011 (Table I in the online-only Data Supplement). AF was defined as a diagnosis of AF or atrial flutter with code 427.92 (ICD-8), 427D (ICD-9), or I48 (ICD-10). Ischemic stroke was defined as code 434 or 436 (ICD-8 and ICD-9) or I63 or I64 (ICD-10). Heart failure was defined as code 427.00 (ICD-8), 428 (ICD-9), or I50 (ICD-10). Operations on the cardiovascular system were classified as codes 30 to 32 (classification of operations, 6th version) or F codes (classification of surgical procedures, version 1.9). 22, 23 We used a hierarchical CHD categorization proposed by Botto et al 24 and subsequently used in other CHD populations studies 25, 26 to classify patients with CHD into 6 different groups according to their lesions. Group 1 comprised patients with conotruncal defects such as a common arterial trunk, transposition of the great vessels, tetralogy of Fallot, or aortopulmonary septum defect. Group 2 comprised patients with nonconotruncal defects such as endocardial cushion defects, a common ventricle, and hypoplastic left heart syndrome. Group 3 comprised patients with coarctation of the aorta. Group 4 comprised patients with ventricular septal defect. Group 5 comprised patients with atrial septal defect. Group 6 included patients with all other heart and circulatory system anomalies and all other CHD diagnoses that were not included in the other 5 lesion groups.
Statistical Analysis
To assess the impact of CHD on the risk of developing AF, we analyzed survival of patients and control subjects born from 1970 to 1993 and followed up until the occurrence of
Clinical Perspective
What Is New?
• We report for the first time in a large, comprehensive, national cohort study the incidence of atrial fibrillation in children and young adults with congenital heart disease.
• Up to the age of 42 years, 1 in 12 patients with congenital heart disease had developed atrial fibrillation, and 1 in 10 with congenital heart disease and atrial fibrillation had developed heart failure.
• In particular, patients with the most complex congenital malformations, conotruncal defects, had the highest risk of developing atrial fibrillation.
• Surgical correction, done in almost 40% of patients with congenital heart disease, was associated with a 3.6-fold higher risk of developing atrial fibrillation.
What Are the Clinical Implications?
• Patients with the most complex congenital malformations, conotruncal defects, had the highest risk and could be considered for targeted monitoring.
• As the congenital heart disease population grows older, conventional risk factors may further add to this arrhythmia burden.
• There is an urgent need for dedicated risk scores for assessing the need for preventive measures and anticoagulation treatment in patients with congenital heart disease. According to the hierarchical CHD classification, the risk of AF was higher in all lesion groups than in control subjects ( Figure 1 ). However, group 1 (conotruncal defects such as tetralogy of Fallot, transposition of the great vessels, common arterial trunk, and aortopulmonary septal defect) had the highest risk of developing AF (HR, 84.27; 95% CI, 56.86-124.89). Even so, patients with less complex heart defects such as coarctation of the aorta and atrial septal defect also had a high excess risk of AF (HR, 24.14; 95% CI, 13.63-42.77; and HR, 22.26; 95% CI, 14.72-33.68, respectively). Figure 2 shows the risk of AF in the study population by sex and lesion group. Patients in group 1 had the highest risk of AF (both men and women); however, although the absolute risk was higher in men than women (429 versus 340 per 100 000 person-years, respectively), the HR was almost twice as high in women (HR, 134.56; 95% CI, 58.14-311.43) as in men (HR, 71.75; 95% CI, 45.80-112.40) because of the low risk in women from the control group.
The highest prevalence of AF and the highest risk of developing AF were found in group 1 regardless of birth period ( Figure I in the online-only Data Supplement). Figure 3 shows the cumulative incidence of AF in the study population with death as a competing risk. The incidence of AF in patients with CHD increased exponentially after the age of 20 years, reaching ≈8.3% at the age of 42 years. The cumulative incidence was increased in all lesion groups; however, patients with conotruncal malformations (group 1) had the highest incidence of AF, reaching almost 20% by the age of 42 years ( Figure 4) . Table 1 shows the excess risk of developing AF in patients with CHD compared with control subjects ac- Figure 1 . Risk of atrial fibrillation (AF) in 6 different lesion groups of patients with congenital heart disease (CHD) compared with matched control subjects. Lesion group 1 was defined as patients with conotruncal defects such as common arterial trunk, transposition of the great vessels, tetralogy of Fallot, or aortopulmonary septum defect. Lesion group 2 was defined as patients with nonconotruncal defects such as endocardial cushion defects, common ventricle, and hypoplastic left heart syndrome. Lesion group 3 was defined as patients with coarctation of the aorta. Lesion group 4 was defined as patients with ventricular septal defect. Lesion group 5 was defined as patients with atrial septal defect. The other group included all other heart and circulatory system anomalies and all other CHD diagnoses that were not included in the other 5 lesion groups. CI indicates confidence interval; and HR, hazard ratio. †All P<0.001. Patients with CHD who underwent operative repair (39.7%) at least once during follow-up had 3.56 times higher (95% CI, 3.03-4.18) risk of developing AF compared with patients with CHD who were not operated on before the end of the study. The highest risk was in patients with atrial septal defect (lesion group 5; HR, 5.04; 95% CI, 3.94-6.22). Table 2 shows the prevalence of major complications after an AF diagnosis in patients with CHD and control subjects. Heart failure was the most frequent complication after AF. It was found in 10.7% of patients with CHD and 2.7% of control subjects, and the risk was 4 times higher in patients with CHD than in control subjects at a mean age of 27.1 and 28.5 years, respectively. Ischemic stroke was diagnosed in 2.1% of patients with CHD with AF and 0.6% of control subjects with AF.
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Using time-dependent analysis, we found that the risk of heart failure was significantly 11.35 times higher (95% CI, 8.62-14.93) in patients with CHD and AF compared with those without AF. The risk for ischemic stroke was also increased (HR, 2.49; 95% CI, 1.42-4.22) in patients with CHD and AF compared with patients without AF. Finally, the risk of death was 5.53 times higher (95% CI, 4.27-7.17) in patients with CHD and AF than in patients without AF.
All diagnoses of ischemic stroke in patients with CHD and their control subjects were based on a hospitalization. However, all patients with CHD (n=70) and all control subjects (n=9) who developed heart failure were diagnosed in connection with an outpatient visit.
The cumulative incidence of AF increased exponentially in both men and women of the study population during adulthood ( Figure 5 ). Men with CHD had a higher incidence than women with CHD starting from the midteens, with a final cumulative incidence at the age of 42 years of 11% and 6% in men and women, respectively.
DISCUSSION
In the present study, we compared the risk of developing AF in patients with CHD and matched control subjects from birth to 42 years of age. The main finding was that the risk of AF was 22 times greater in patients with CHD than in control subjects and that the presence of complex heart malformations carried the highest risk of developing AF. The cumulative risk increased almost exponentially during adulthood; at 42 years of age, 1 in Figure 2 . Risk of atrial fibrillation (AF) in the study population according to sex and lesion group. Lesion group 1 was defined as patients with conotruncal defects such as common arterial trunk, transposition of the great vessels, tetralogy of Fallot, or aortopulmonary septum defect. Lesion group 2 was defined as patients with nonconotruncal defects such as endocardial cushion defects, common ventricle, and hypoplastic left heart syndrome. Lesion group 3 was defined as patients with coarctation of the aorta. Lesion group 4 was defined as patients with ventricular septal defect. Lesion group 5 was defined as patients with atrial septal defect. The other group included all other heart and circulatory system anomalies and all other CHD diagnoses that were not included in the other 5 lesion groups. CI indicates confidence interval; CHD, congenital heart disease; and HR, hazard ratio. †All P<0.001. 12 patients with CHD had been diagnosed with AF, and among patients with complex CHD, 1 of 5 had developed AF at that age.
According to a Danish register study 14 that used a study design similar to ours, the risk of AF in adult patients with atrial septal defect was 18.5 times higher with closure and 16.4 times higher without closure compared with matched control subjects during a mean follow-up of 24 years. We found that the risk of AF was 22.3 times higher in patients with atrial septal defect than in matched control subjects during a mean follow-up of 27 years. An association between right atrial dilatation and AF in patients with CHD such as Ebstein anomaly has also been described. [15] [16] [17] A cross-sectional study from Toronto showed that the prevalence of AF and atrial flutter was markedly increased in patients with tetralogy of Fallot who were >45 years of age and was predominantly associated with left-sided heart disease. 18 In the present study, the most frequent complication in patients with CHD who developed AF was heart failure, and 1 of 10 of these patients developed heart failure by the age of 42 years. This finding raises the question of whether AF may be a marker for incipient heart failure. However, the complexity, heterogeneity, and lack of knowledge about how to prevent or treat heart failure in this patient group indicate the need for further research to elucidate how to prevent this major complication.
In patients without CHD, several clinical trials have shown a significant reduction in the risk of developing AF among patients with hypertension, myocardial infarction, or heart failure who are treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. 27 Data on the effectiveness of both heart failure treatment and AF prevention in patients with CHD are still missing. Furthermore, despite the clinical benefits of lifetime anticoagulation ther- 
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Atrial Fibrillation in Congenital Heart Disease ORIGINAL RESEARCH ARTICLE apy in patients with AF and a high risk of stroke, 28, 29 an unknown proportion of patients with CHD and AF are assumed to be at low risk of stroke because of their generally low age and thus may remain untreated. This may contribute to a recent observation that the relative risk of ischemic stroke in young patients with CHD was >10 times higher than that in the general population; however, the absolute risk for Figure 4 . Cumulative incidence of atrial fibrillation in patients with congenital heart disease (CHD) and control subjects according to a hierarchical classification. Lesion group 1 was defined as patients with conotruncal defects such as common arterial trunk, transposition of the great vessels, tetralogy of Fallot, or aortopulmonary septum defect. Lesion group 2 was defined as patients with nonconotruncal defects such as endocardial cushion defects, common ventricle, and hypoplastic left heart syndrome. Lesion group 3 was defined as patients with coarctation of the aorta. Lesion group 4 was defined as patients with ventricular septal defect. Lesion group 5 was defined as patients with atrial septal defect. The other group included all other heart and circulatory system anomalies and all other CHD diagnoses that were not included in the other 5 lesion groups. AF indicates atrial fibrillation; CHD, congenital heart disease; and CI, confidence interval.
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ischemic stroke was low. 21 The CHADS 2 and CHA 2 DS 2 -VASc clinical risk scores, which are commonly used to evaluate the stroke risk, may be of limited value in the CHD population because these scores are derived mainly from and validated in patients without CHD and stem from clinically very different and much older patient cohorts. 30, 31 Recent studies have reported a significantly higher relative risk of ischemic stroke in young patients with CHD than in control subjects and have shown that AF is strongly associated with the development of ischemic stroke and heart failure in those patients. 21, 32 Our results adds further strength to this observation, but since the absolute risk is low, the concept of early detection, diagnosis, and treatment of AF in patients with CHD to prevent complications such as heart failure and ischemic stroke remains hypothetical and warrants further research.
A question that emerges is whether AF is an early marker of worsening of the underlying heart disease. AF indicates atrial fibrillation; CHD, congenital heart disease; CI, confidence interval; and IQR, interquartile range. 
We found that patients with CHD and AF have a significantly increased risk for adverse outcomes such as heart failure, ischemic stroke, and death compared with patients with CHD without AF. Of 654 patients with CHD and AF, 506 did not develop any adverse outcome, and this may suggest that the development of AF in patients with CHD is not primarily a marker of worsening the underlying CHD, but ultimately, this issue cannot be definitely resolved from our data.
In addition, patients with the complex CHD as in lesion group 1 (conotruncal malformations) had the highest risk of developing AF and adverse outcomes. However, as with any CHD classification system, it is by definition very limited in the description of the underlying condition in each lesion group, and larger studies with more detailed data sets are needed to identify the underling mechanisms of the association of a certain CHD subgroup with AF.
A population-based study from Quebec in Canada found the prevalence of atrial arrhythmias to be 3 times higher in patients with CHD than in the general population but did not separate between various forms of atrial arrhythmias; that is, episodic supraventricular tachycardia and other atrial arrhythmias were also included. 8 Our results show that the prevalence of AF was 19.9 times higher in young patients with CHD compared with matched control subjects from the general population. Bouchardy et al 8 estimated the risk for an 18-year-old patient with CHD of developing atrial arrhythmia up to the age of 65 years at ≈50%, but this projection was based on the results from before the modern era of advanced, early cardiac repair with modern techniques and low perioperative and postoperative mortality. However, their study population did not have a control group without CHD, and the median age of patients with CHD and atrial arrhythmias was 70 years, reflecting an earlier era of congenital heart surgery, in combination with advancing age. How much of the postulated increase in risk was from each source is difficult to determine. The excess risk of atrial arrhythmias in patients with CHD is an example of the notion that "patients with CHD are young patients with aged hearts." 8 Although this may have been true in the earlier era and in nonoperated patients still surviving into old age, it is perhaps less representative of the current era in which >95% of the patients will reach adulthood. 19 Our data provide information on the risk for AF for young patients operated on in the current era and in comparison with patients without CHD.
Furthermore, we found that patients with CHD who had been operated on had an almost 4-fold increased risk of developing AF than unrepaired patients with CHD. This may reflect more complex disease in repaired patients compared with unrepaired patients. It may also reflect the impact of scar tissue in the atrial wall. 33 Validated prediction scores are widely used in clinical practice to estimate the stroke risk in patients with AF, and lifetime anticoagulation treatment is indicated if the risk is high; however, those scores are generally based on cohorts from the general population, not on young patients with CHD. [29] [30] [31] There is currently a lack of knowledge about the estimation of the stroke risk in patients with CHD with AF, resulting in exposure to an increased risk of ischemic stroke in this vulnerable group, who may still remain largely without anticoagulation treatment. Although ischemic stroke is uncommon in patients with CHD in absolute terms, there is an annual risk of 0.3% and a cumulative risk starting from an average age of 27 years, making ischemic stroke ≈10 times more common among patients with CHD compared with control subjects. 21 However, the magnitude of the risk of ischemic stroke events in patients with CHD >42 years of age is still unknown. Our results should encourage physicians involved in the care of children and young adults to look for AF in patients with CHD in general and in patients with conotruncal defects in particular. Our patients were all <42 years of age, and although risk scoring with CHA 2 DS 2 -VASc may not be appropriate given the age span of our patients, acquired risk factors as they grow older may further increase the risk of AF and its consequences.
Our study has several strengths, but it also has limitations. It was a nationwide study, and all patients with a CHD diagnosis were matched from birth with control subjects from the general population. This decreases the risk of selection bias, although coding and ascertainment bias may still be present. The risk of AF between patients with CHD and control subjects may be overestimated in our study because asymptomatic or paroxysmal AF may not be detected in the general population to the same extent as in patients with CHD, who are under more frequent medical supervision than control subjects. Because the national primary care register was not included in our study, we may have missed some patients with CHD or control subjects with AF managed in primary care only. However, patients with CHD who have contact with only primary care are likely to be very few in number and probably have less complex CHD.
Future studies should develop and validate a dedicated scoring system to determine the individual risk for development of AF and the clinical consequences of AF. This will increase the possibilities to target screening efforts and preventive measures such as ablation, device therapy, and anticoagulants to patients at particularly high risk. The establishment of research networks and large, high-quality registers for patients with CHD will be paramount to such efforts.
Conclusions
Although the absolute risk of developing AF in children and young adults with CHD was low, the relative risk 
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was 22 times higher than that in matched control subjects. One fifth of patients with conotruncal congenital defects were diagnosed with AF by the age of 42 years. Patients with conotruncal malformations carried most of the AF risk and should be considered for targeted intervention because, once diagnosed with AF, they also have a high risk of major complications. Finally, the risk of heart failure and death was significantly higher than the risk of ischemic stroke among patients with CHD with AF.
